Search Results 261-270 of 6006 for albumin

  1. ALPN-202 With PD-1 Inhibition in Advanced Malignancies - Mayo Clinic

    The purpose of this study is to evaluate ALPN-202 with PD-1 inhibition to treat adults with advanced solid tumors or lymphoma. Participation eligibility.

  2. Intra-patient Dose Escalation Study Evaluating Efficacy, Safety and Pharmacokinetics of Pasireotide (SOM230) Subcutaneous (s.c.) Followed by Pasireotide LAR in Patients with Dumping Syndrome - Mayo Clinic

    ... albumin ≥3.5g/dl at baseline; Patients with gastric cancer must have a negative CT or MRI scan (total abdomen); Karnofsky Performance Status ≥ 60 (i.e. ...

  3. Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma - Mayo Clinic

    ... albumin; Note: Patients with an initial magnesium < 0.5 mmol/L (1.2 mg/dl) may receive corrective magnesium supplementation but should continue to receive ...

  4. Radiation Therapy with or without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer - Mayo Clinic

    Participation eligibility · Serum calcium (ionized or adjusted for albumin) < 7 mg/dL or > 12.5 mg/dL* · Glucose < 40 mg/dL or > 250 mg/dL · Magnesium < 0.9 mg/dL ...

  5. Mayo Clinic

    ... . VID-20127976. Home; Brightcove-Brachial Plexus Injury Patient Story-Single. Have 2X the impact! Give Today. Make a gift that can go twice as far to ...

  6. A Study Comparing Combination Chemotherapy to Gemcitabine Hydrochloride and Nab-Paclitaxel Given Before Surgery for Treating Patients who have Pancreatic Cancer that can be Removed by Surgery - Mayo Clinic

    Serum albumin ≥ 3 g/dL; Serum creatinine ≤ IULN within 14 days prior to registration; Sites must seek additional patient consent for the future use of ...

  7. Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia or Lobular Carcinoma In Situ - Mayo Clinic

    - Albumin, S > 1.5 x ULN (within 30 days of randomization). - Protein, total, S > 1.5 x ULN (within 30 days of randomization). - Creatinine > 1.5 x ULN ...

  8. Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid - Mayo Clinic

    Albumin <3.5 g/dL; Presence of clinical complications of PBC or clinically significant hepatic decompensation, including: Current Model for End-Stage Liver ...

  9. Mayo Clinic

    Share · Tweet . VID-20115891. Home; Brightcove-Stroke Patient Story. Have 2X the impact! Give Today. Make a gift that can go twice as far to advance ...

  10. A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies - Mayo Clinic

    Albumin ≥ 3.0 g/dL;; Creatinine clearance or eGFR ≥ 30 mL/min as estimated by the Cockcroft-Gault equation;; AST/ALT ≤ 2 x ULN. If documented liver ...